Todd Berry

Todd has more than 30 years of experience auditing and advising middle-market, privately held, venture backed and multi-national public life sciences and technology companies. Todd is the national co-leader as well as leader of the BDO Boston Life Science practice and has worked with various life sciences companies through the years including, CPEX, Nimbus Discovery, iCad, Inc., ImmunoGen, Inc., DecImmune Therapeutics, Inc., Genta Pharmaceuticals, as well as Ocata, Agilis, Theracos, GEN9, Exact Sciences, Aldeyra, and T2 Biosystems. 

In addition to Todd’s experience providing professional services to such companies, he also spent several years in financial operating positions with two technology startups. Todd’s background includes significant experience auditing and advising companies in the area of revenue recognition, share-based compensation, pre-IPO planning, mergers and acquisitions, valuation issues, and complex equity and debt transactions.  

His transactional experience in the area of venture capital transactions, initial public offerings and mergers and acquisitions has amounted to the generation of capital/value in excess of $1 billion. 

In Todd’s role as National Co-Leader of Life Sciences he is responsible for the overall go to market strategy, learning and development, service line integration, market assessments, marketing and brand awareness, client satisfaction, knowledge sharing and assurance quality initiatives.

Todd is also an Assurance National Engagement Quality Review Principal.